---

Vitamin D3 + Vitamin K2 is a fat-soluble vitamin combination pairing cholecalciferol, a vitamin D form produced in skin after UV exposure and obtained from foods or supplements, with vitamin K2 menaquinones found in foods and studied in human research for bone mineral density, osteocalcin carboxylation, vascular calcification, and glycemic biomarkers (NIH ODS) (NIH ODS) (Review).

Human evidence for Vitamin D3 + Vitamin K2 is most developed in Bone Health, where randomized trials have examined bone mineral density and vitamin K–dependent osteocalcin activation in postmenopausal women (Research) (Review). Cardiovascular studies have tested vitamin K2 with vitamin D3 for coronary artery calcification and related vascular outcomes, with findings that vary by population and baseline calcification burden (Research) (Research). A smaller human trial has examined D3+K2 in Diabetes and Glycemic Control, while broader vitamin D + vitamin K reviews describe biologically plausible overlap but emphasize heterogeneity in study design, dose, and endpoints (Research) (Review).

Ingredient Identity

• Official name(s): Vitamin D3 + Vitamin K2; cholecalciferol + menaquinones (NIH ODS) (NIH ODS).
• Synonyms: D3 + K2; cholecalciferol + menaquinone; vitamin D + menaquinone combination (NIH ODS) (NIH ODS).
• Classification: Fat-soluble vitamin combination, usually combining a vitamin D form with a vitamin K2 form such as MK-4 or MK-7 (NIH ODS) (NIH ODS).
• CAS number: The combination is not a single chemical entity, so CAS numbers depend on the specific ingredient forms used rather than on “D3+K2” as a combined ingredient (NIH ODS) (NIH ODS).
• Endogenous vs exogenous: Vitamin D3 can be produced in human skin after ultraviolet exposure and can also be consumed, while vitamin K is obtained from diet and includes multiple forms such as phylloquinone and menaquinones (NIH ODS) (NIH ODS).

Ingredient Snapshot

• Classification: Vitamin D3 + Vitamin K2 is a fat-soluble vitamin pairing used in human research to study overlapping roles in calcium handling, bone metabolism, and vitamin K–dependent proteins (NIH ODS) (Review).
• Endogenous vs exogenous status: Vitamin D3 has both endogenous and dietary sources, while vitamin K2 is treated nutritionally as an exogenous vitamin K form (NIH ODS) (NIH ODS).
• Primary human research domains: The main studied domains are Bone Health, Cardiovascular Health, Nutrition and Deficiencies, and Diabetes and Glycemic Control (Research) (Research) (Research).
• Common study formats: Human research includes randomized trials, postmenopausal bone studies, vascular calcification trials, biomarker studies, and meta-analyses of vitamin D + vitamin K interventions (Review) (Review).
• Pharmacokinetic characterization status: Component-level pharmacokinetics are better characterized than the combined D3+K2 product category, with human studies separately examining oral vitamin D absorption and MK-7 bioavailability (Review) (Research).
• Regulatory context (U.S./EU): In the United States, dietary supplements are regulated as foods rather than drugs, while EFSA has published dietary reference value opinions for vitamin D and vitamin K in the European context (FDA) (EFSA) (EFSA).
• Evidence maturity: The overall evidence is best described as Limited / Mixed, with moderate clinical depth for bone biomarkers and BMD, mixed cardiovascular findings, and smaller early-stage evidence for glycemic outcomes (Review) (Research) (Research).

Introduction

Vitamin D3 is a vitamin D form that humans can synthesize in skin after ultraviolet exposure and can also obtain from certain foods or supplements, while vitamin K2 refers to menaquinone forms within the vitamin K family (NIH ODS) (NIH ODS). These vitamins are often discussed together because vitamin D is involved in calcium balance and bone metabolism, while vitamin K is required for the activation of proteins such as osteocalcin and matrix Gla protein that participate in bone and vascular biology (Review).

People commonly look up D3+K2 because the combination appears in research on bone mineral density, osteocalcin carboxylation, vascular calcification, and selected metabolic biomarkers (Review) (Research) (Research). The evidence has attracted interest because several studies examine whether pairing vitamin D with vitamin K modifies outcomes differently than vitamin D, calcium, minerals, or vitamin K alone, although trial results are not uniform across populations and endpoints (Research) (Review).

This article is informational only, describes Vitamin D3 + Vitamin K2 as a biochemical and nutritional combination studied in human research, and does not provide medical or dosing advice.

Quick Summary

• Vitamin D3 + Vitamin K2 combines cholecalciferol with menaquinone forms of vitamin K, and human studies mainly examine bone, vascular, and biomarker outcomes rather than general wellness claims (NIH ODS) (NIH ODS).
• The strongest human evidence area is Bone Health, where randomized trials and meta-analyses have measured BMD and undercarboxylated osteocalcin in postmenopausal or older adult populations (Research) (Review).
• Cardiovascular research has studied vascular elasticity and coronary artery calcification, but findings vary across K1, K2, vitamin D, mineral, and calcification-burden contexts (Research) (Research) (Research).
• A small randomized trial in adults with type 2 diabetes studied 1,000 IU/day vitamin D3 plus 100 µg/day vitamin K2 and reported changes in glycemic and osteocalcin-related biomarkers over 3 months (Research).
• MK-7 and MK-4 are different vitamin K2 forms, and human pharmacokinetic studies show that K2 form can matter for blood-level response after oral intake (Research) (Research).
• Vitamin K can interact with warfarin, and vitamin D safety discussions include excess-intake concerns such as hypercalcemia in susceptible contexts (NIH ODS) (NIH ODS).
• D3+K2 evidence is not a single uniform literature because studies differ by vitamin K form, D3 versus active vitamin D analogs, calcium or mineral co-use, baseline nutrient status, age, sex, and outcome measured (Review) (Review).

Human Research Findings by Condition

Bone Health

Human research on Bone Health includes randomized trials in postmenopausal women and older adults, often measuring BMD, undercarboxylated osteocalcin, and bone-turnover markers (Research) (Review). Findings are mixed: some studies reported site-specific BMD or biomarker improvements, while longer MK-7 add-on trials did not consistently show significant BMD differences compared with calcium and vitamin D background supplementation (Research) (Review).

Key human study

Dose studied: 45 mg/day vitamin K2 plus calcium 630 mg/day and vitamin D 400 IU/day
Population: Korean postmenopausal women over 60
Duration: 6 months

Researchers compared calcium + vitamin D with and without added vitamin K2 in postmenopausal women and measured lumbar-spine BMD and undercarboxylated osteocalcin (Research). The vitamin K2 add-on group showed increased L3 BMD and reduced undercarboxylated osteocalcin compared with the calcium + vitamin D group (Research).

Result: Human clinical study reported a modest improvement (Research)
Evidence strength: Limited to Moderate
Study source: (Research)

Additional human study

Dose studied: 375 µg/day MK-7 added to calcium and vitamin D background supplementation
Population: Postmenopausal women with osteopenia
Duration: 3 years

A randomized placebo-controlled trial tested MK-7 as an add-on to calcium and vitamin D in postmenopausal women with osteopenia (Research). BMD declined over time at measured sites, and the trial did not report significant between-group BMD differences favoring MK-7 (Research).

Result: Human clinical study reported no clear effect (Research)
Evidence strength: Mixed
Study source: (Research)

Cardiovascular Health

Human Cardiovascular Health research has studied carotid elasticity, coronary artery calcification, aortic valve calcification, and arterial microcalcification designs using vitamin D with vitamin K forms (Research) (Research) (Research). Findings are not uniform because studies differ by vitamin K form, vascular endpoint, baseline calcification severity, and whether the intervention includes minerals or calcium (Review).

Key human study

Dose studied: 720 µg/day vitamin K2 plus 25 µg/day vitamin D3
Population: Adults with coronary artery calcification score ≥400 AU
Duration: 24 months

A multicenter double-blind randomized trial tested vitamin K2 plus vitamin D3 in participants with severe coronary artery calcification (Research). The trial reported reduced coronary artery calcification progression over 24 months compared with placebo in this high-calcification population (Research).

Result: Randomized human trial reported a statistically significant improvement (Research)
Evidence strength: Moderate
Study source: (Research)

Additional human study

Dose studied: 720 µg/day vitamin K2 plus 25 µg/day vitamin D
Population: Men with aortic valve calcification and no prior ischemic heart disease in a secondary coronary analysis
Duration: 2 years

A secondary analysis from the AVADEC trial evaluated coronary artery calcification progression in men receiving vitamin K2 plus vitamin D (Research). The analysis found no significant overall reduction in mean coronary artery calcification progression, while subgroup findings in participants with higher baseline CAC were described as hypothesis-generating (Research).

Result: Human clinical studies reported mixed findings (Research)
Evidence strength: Mixed
Study source: (Research)

Diabetes and Glycemic Control

Human evidence in Diabetes and Glycemic Control is smaller than the bone and cardiovascular literature, but one randomized trial directly compared vitamin D3, vitamin K2, and their combination in adults with type 2 diabetes (Research). The study measured glycemic outcomes and osteocalcin-related biomarkers, making it a biomarker-focused metabolic trial rather than a long-term diabetes outcomes study (Research).

Key human study

Dose studied: 1,000 IU/day vitamin D3 plus 100 µg/day vitamin K2
Population: Adults with type 2 diabetes
Duration: 3 months

A double-blind randomized clinical trial compared vitamin D3, vitamin K2, D3+K2, and control conditions in 40 adults with type 2 diabetes (Research). The D3+K2 group showed reductions in glycemic measures and in the undercarboxylated-to-carboxylated osteocalcin index over the study period (Research).

Result: Human clinical study reported a modest improvement (Research)
Evidence strength: Emerging
Study source: (Research)

Nutrition and Deficiencies

Human research in Nutrition and Deficiencies has focused on vitamin K–dependent biomarkers such as undercarboxylated osteocalcin and on how vitamin K status markers respond when vitamin K is added to vitamin D or calcium backgrounds (Research) (Research). These studies are useful for understanding nutrient biology, but biomarker improvement does not automatically establish long-term clinical outcomes (Research).

Key human study

Dose studied: 45 mg/day vitamin K2 with or without 0.75 µg/day alfacalcidol
Population: Early postmenopausal women with low BMD
Duration: 1 year

A randomized study compared vitamin K2 alone with vitamin K2 plus alfacalcidol, an active vitamin D analog, in early postmenopausal women (Research). Both groups showed reductions in undercarboxylated osteocalcin, and the combination group showed additional changes in bone-turnover markers (Research).

Result: Human studies observed short-term physiological effects (Research)
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: 500 µg/day phylloquinone plus 600 mg/day calcium and 400 IU/day vitamin D
Population: Adults aged 60–80
Duration: 3 years

A double-blind trial tested whether adding vitamin K1 to calcium and vitamin D improved bone outcomes and vitamin K biomarkers in older adults (Research). Vitamin K biomarkers improved, but BMD did not differ from the calcium + vitamin D control group (Research).

Result: Human clinical study reported no clear effect (Research)
Evidence strength: Mixed
Study source: (Research)

Aging and Longevity Research

Human studies relevant to Aging and Longevity Research have mainly examined older adult or postmenopausal populations with age-associated bone and vascular endpoints, not lifespan extension or longevity outcomes (Research) (Research). The evidence should therefore be read as research on aging-related bone and vascular markers rather than as evidence for life extension (Research) (Review).

Key human study

Dose studied: 200 µg/day vitamin K1 plus 10 µg/day vitamin D3 and 1,000 mg/day calcium
Population: Older women
Duration: 2 years

A randomized trial in 244 older women compared vitamin K1, vitamin D3, and calcium combinations and measured skeletal outcomes (Research). The combined vitamin K1 + vitamin D3 + calcium group showed a modest increase in ultradistal-radius BMD/BMC, while effects were not consistent across all skeletal sites (Research).

Result: Human clinical study reported a modest improvement (Research)
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: 1 mg/day vitamin K1 plus 8 µg/day vitamin D with minerals
Population: Postmenopausal women
Duration: 3 years

A randomized study tested minerals plus vitamin D with or without vitamin K1 and measured carotid artery elastic properties (Research). The vitamin K1 + vitamin D + mineral group maintained carotid elastic properties better than comparator groups over 3 years (Research).

Result: Human clinical study reported a modest improvement (Research)
Evidence strength: Limited to Moderate
Study source: (Research)

Dosage & Study Snapshot (Research Context)

Human studies have used several exposure patterns: direct D3+K2 combinations, active vitamin D analog + K2 combinations, vitamin K add-on designs on calcium/vitamin D backgrounds, and adjacent vitamin D + K1 studies (Research) (Research) (Research). The dose bands below describe research exposures only and should not be read as dosing advice, because populations, forms, background calcium or mineral use, and endpoints differed across studies (Review).

0.75 µg/day alfacalcidol + 45 mg/day menatetrenone:

This low-microgram vitamin D-family exposure used alfacalcidol, an active vitamin D analog, rather than ordinary cholecalciferol D3 (Research). It was paired with high-dose menatetrenone, a vitamin K2 MK-4 form, in postmenopausal osteoporosis research (Research). The study compared single and combined treatments for lumbar-spine BMD and related bone outcomes (Research). This exposure is important because it is not directly interchangeable with common D3+K2 supplement formats that use cholecalciferol and lower microgram-range MK-7 (Research).

Result: Mixed findings (Research)
Evidence strength: Limited
Notes / limitations: This band uses a vitamin D analog, so it is adjacent to but not identical with standard D3+K2 supplementation.

8–10 µg/day vitamin D with 200 µg–1 mg/day vitamin K1:

Several older-adult trials studied vitamin D with vitamin K1 rather than K2, often with calcium or minerals included in the intervention (Research) (Research). One 2-year trial used 10 µg/day vitamin D3 with 200 µg/day vitamin K1 and calcium in older women and reported modest site-specific skeletal effects (Research). A 3-year trial used 8 µg/day vitamin D with 1 mg/day vitamin K1 and minerals and reported maintained carotid elastic properties in postmenopausal women (Research). These studies help frame the broader vitamin D + vitamin K concept but should not be treated as direct K2 evidence (Research).

Result: Modest improvement (Research) (Research)
Evidence strength: Limited
Notes / limitations: These studies used K1, not K2, so they provide adjacent evidence rather than direct D3+K2 evidence.

1,000 IU/day vitamin D3 + 100 µg/day vitamin K2:

A 3-month randomized trial in adults with type 2 diabetes used 1,000 IU/day vitamin D3 with 100 µg/day vitamin K2 in a direct D3+K2 combination arm (Research). The trial compared D3 alone, K2 alone, D3+K2, and control groups and measured glycemic biomarkers and osteocalcin-related markers (Research). The combination arm reported reductions in glycemia and in the undercarboxylated-to-carboxylated osteocalcin index over 3 months (Research). This is one of the clearest direct D3+K2 human studies outside bone-focused postmenopausal research (Research).

Result: Modest improvement (Research)
Evidence strength: Emerging
Notes / limitations: The trial was small and short, so it does not establish long-term diabetes outcomes.

375 µg/day MK-7 with calcium and vitamin D background supplementation:

Postmenopausal osteopenia trials have tested 375 µg/day MK-7 on a background of calcium and vitamin D intake or supplementation (Research) (Research). A 12-month study examined BMD, HRpQCT microarchitecture, and bone markers, while a 3-year randomized study examined longer-term BMD change (Research) (Research). The 3-year trial did not report significant between-group BMD differences favoring MK-7 over placebo when both groups received calcium and vitamin D background support (Research). This band is useful because it reflects MK-7 add-on research rather than high-dose MK-4 research (Research).

Result: No clear effect (Research)
Evidence strength: Mixed
Notes / limitations: The vitamin D exposure was background supplementation rather than a clean fixed D3+K2-only intervention.

25 µg/day vitamin D3 + 720 µg/day vitamin K2:

Cardiovascular calcification trials have used 25 µg/day vitamin D3 with 720 µg/day vitamin K2 in adults with vascular calcification (Research) (Research). The AVADEC coronary analysis found no significant overall reduction in mean coronary artery calcification progression, although higher-baseline-CAC subgroup results were described as hypothesis-generating (Research). The DANCODE trial in adults with CAC ≥400 AU reported reduced CAC progression over 24 months versus placebo (Research). This dose band is therefore best interpreted as cardiovascular-research exposure in selected calcification populations rather than as a general D3+K2 outcome pattern (Research) (Research).

Result: Mixed findings (Research) (Research)
Evidence strength: Moderate
Notes / limitations: Cardiovascular findings appear sensitive to baseline calcification burden and endpoint selection.

45 mg/day menatetrenone with vitamin D or active vitamin D analogs:

Several Japanese and Korean bone studies used 45 mg/day menatetrenone, an MK-4 form of vitamin K2, either with vitamin D, calcium, or active vitamin D analogs (Research) (Research) (Research). These trials measured lumbar-spine BMD, osteocalcin carboxylation, and bone-turnover markers in postmenopausal women or low-BMD populations (Research) (Research). Some studies reported favorable changes in BMD or vitamin K–dependent biomarkers, but the wider literature includes mixed findings depending on study design and comparator (Review). This band differs markedly from microgram-range MK-7 studies and should be interpreted as form-specific MK-4 evidence (Research).

Result: Mixed findings (Research) (Review)
Evidence strength: Moderate for biomarkers; mixed for clinical endpoints
Notes / limitations: MK-4 milligram dosing and MK-7 microgram dosing should not be treated as interchangeable.

Key Takeaways from Human Research

• The most developed D3+K2-related human evidence is in Bone Health, especially BMD and undercarboxylated osteocalcin outcomes in postmenopausal women and older adults (Review) (Research).
• Cardiovascular trials have examined coronary artery calcification and vessel measures, but results differ between overall trial findings, subgroup analyses, and severe-CAC populations (Research) (Research).
• D3+K2 glycemic research includes a small randomized trial in type 2 diabetes, so this area is better described as emerging rather than established (Research).
• Human studies differ substantially by K2 form, vitamin D form, calcium or mineral co-use, and baseline nutrient or calcification status, which limits simple conclusions across all D3+K2 products (Review) (Review).
• Safety interpretation should account for vitamin K interactions with warfarin and vitamin D excess-intake concerns described by NIH ODS (NIH ODS) (NIH ODS).

Origin & Natural Occurrence

Vitamin D3 is produced in human skin when ultraviolet radiation converts a cholesterol-derived precursor into vitamin D3, and it is also present in some foods and dietary supplements (NIH ODS). Vitamin K includes phylloquinone and menaquinones, and menaquinones are the vitamin K2 forms commonly discussed in D3+K2 combinations (NIH ODS).

Vitamin K2 occurs in certain animal-derived and fermented foods, while vitamin K1 is more closely associated with green leafy vegetables (NIH ODS). Research combinations may use vitamin K2 forms such as MK-4 or MK-7, and the human literature should distinguish those forms because their study doses and pharmacokinetic profiles differ (Research) (Research).

Manufacturing origin varies by formulation, because D3+K2 products may combine cholecalciferol with isolated or fermented-source menaquinones, while clinical studies may use specific forms such as menatetrenone or MK-7 (Research) (Research). The research interpretation depends on the actual forms used, because vitamin K1, MK-4, and MK-7 are not identical exposures (NIH ODS) (Research).

How It Behaves in the Body

In plain language, vitamin D helps the body manage calcium availability, while vitamin K helps activate proteins that need vitamin K–dependent modification before they function normally (NIH ODS) (NIH ODS). This is why D3+K2 research often focuses on bone and vascular tissues, where calcium handling and vitamin K–dependent proteins are biologically relevant (Review).

Vitamin K participates in carboxylation, a biochemical process that changes certain proteins so they can bind calcium more effectively (NIH ODS). Osteocalcin is one such protein studied in bone research, and undercarboxylated osteocalcin is often measured as a marker of vitamin K–related protein activation (Research) (Research).

Vitamin D3 is converted in the body into circulating and active vitamin D metabolites, and vitamin D status is commonly evaluated through 25-hydroxyvitamin D in human research and clinical nutrition contexts (NIH ODS). Vitamin D absorption and metabolism are influenced by gastrointestinal handling and by the specific vitamin D form, with 25-hydroxyvitamin D generally described as better absorbed than nonhydroxylated vitamin D forms in absorption research (Review).

For vitamin K2, human pharmacokinetic work shows that menaquinone form matters, because MK-4 and MK-7 can produce different blood-level response patterns after oral intake (Research). MK-7 has also been studied in single-dose human bioavailability research, which helps explain why some clinical trials use MK-7 microgram dosing rather than MK-4 milligram dosing (Research).

The most established human evidence concerns biomarkers and intermediate outcomes such as BMD, undercarboxylated osteocalcin, and calcification progression, while long-term clinical outcomes remain less consistently established across populations (Review) (Review). Mechanistic explanations are plausible, but they should not be treated as proof of treatment, prevention, or cure without direct clinical outcome evidence (Review).

Absorption & Delivery Formats

Oral immediate-release: Published human studies of D3+K2 and related vitamin D + K interventions primarily use oral formats such as capsules, tablets, or supplement-style interventions (Research) (Research). Oral delivery is also the format used in MK-7 pharmacokinetic and bioavailability research (Research).

Oral extended-release: The cited human studies do not establish a separate evidence base for extended-release D3+K2 formats (Research) (Research). Claims about extended-release effects would require formulation-specific human evidence.

Sublingual: The cited D3+K2 human trials do not provide sublingual-specific pharmacokinetic or clinical outcome evidence (Research) (Research). Sublingual delivery should therefore not be assumed equivalent to oral trial formats without direct comparative data.

Transdermal: The cited human research does not establish transdermal D3+K2 delivery as a studied format for the outcomes reviewed here (Review). Evidence interpretation should remain tied to the oral interventions used in published trials.

Injectable / IV: The D3+K2 human research summarized here does not rely on injectable or IV delivery formats (Research) (Research). Injectable or IV vitamin therapies would require separate clinical and regulatory evaluation.

Quick Facts at a Glance

Onset (reported): D3+K2 clinical trials usually measure outcomes over months or years rather than immediate onset, so onset is best described by biomarker or endpoint timing rather than rapid subjective effects (Research) (Research). A 3-month diabetes trial measured glycemic and osteocalcin-related outcomes, while cardiovascular calcification trials measured changes over 2 years (Research) (Research).

Time to peak (Tmax): A unified Tmax for combined D3+K2 is not established by the outcome trials, because most trials were not designed as combination pharmacokinetic studies (Research) (Research). MK-7 has separate human bioavailability research after oral dosing, and vitamin D absorption has separate component-level reviews (Research) (Review).

Half-life (t½): The clinical outcome trials do not provide a single combined half-life for D3+K2 (Research) (Research). Component-level interpretation is more appropriate because vitamin D and vitamin K forms follow different absorption, transport, and metabolism patterns (Review) (Research).

Typical duration: Human trials commonly run from 3 months to 3 years depending on endpoint and population (Research) (Research) (Research). Shorter studies often emphasize biomarkers, while longer studies more often examine BMD or calcification progression (Research) (Research).

Absorption routes studied: The evidence base reviewed here primarily concerns oral intake (Research) (Review). Vitamin D absorption is described through gastrointestinal handling, while MK-7 oral bioavailability has been studied directly in humans (Review) (Research).

Formulation differences: Vitamin K form is a major interpretation factor because K1, MK-4, and MK-7 are not the same exposure in research (NIH ODS) (Research). Vitamin D form also matters because some trials use cholecalciferol while others use active vitamin D analogs such as alfacalcidol (Research).

Variability drivers: Baseline calcification burden, age, postmenopausal status, background calcium or mineral use, vitamin K form, and endpoint selection can all affect interpretation of the human evidence (Research) (Review). These differences help explain why some studies report favorable biomarkers while others do not show consistent BMD or calcification effects (Research) (Research).

Tolerance / adaptation: The cited studies do not establish a clear tolerance pattern for D3+K2 as a combined ingredient (Research) (Research). Safety discussions are better framed around vitamin K interactions, vitamin D excess-intake concerns, and trial-level adverse event monitoring (NIH ODS) (NIH ODS).

Evidence strength snapshot: Evidence is strongest for intermediate bone and nutrient-status biomarkers, mixed for cardiovascular calcification outcomes, and emerging for glycemic biomarkers (Review) (Review) (Research). The evidence base is limited by heterogeneity in forms, doses, populations, and co-interventions (Review).

Safety, Interactions & Regulation

Vitamin D3 and vitamin K2 are fat-soluble vitamins, and safety interpretation should consider each component rather than treating the combination as a single molecule (NIH ODS) (NIH ODS). Vitamin D excess is associated with toxicity concerns such as hypercalcemia, and NIH ODS discusses vitamin D safety in relation to total intake and health context (NIH ODS). Vitamin K can interact seriously with warfarin, because warfarin works through vitamin K–related pathways (NIH ODS).

A U.S. Pharmacopeial Convention review evaluated MK-7 chemistry, dietary sources, pharmacokinetics, nonclinical toxicity, and clinical safety data (Review). A meta-analysis of vitamin K2 trials in postmenopausal osteoporosis reported no significant difference in pooled adverse reactions between vitamin K2 and control groups in included trials (Review). Cardiovascular D3+K2 trial protocols have included safety monitoring such as serious adverse events and laboratory measures related to calcium, kidney function, phosphate, and coagulation-related variables (Research).

In the United States, FDA states that dietary supplements are regulated as food, not as drugs (FDA). FDA also states that dietary supplement firms are responsible for evaluating the safety and labeling of their products before marketing (FDA). FDA states that products intended to treat, prevent, cure, diagnose, or mitigate disease are drugs rather than dietary supplements (FDA).

In the European context, EFSA has published dietary reference values for vitamin D and vitamin K (EFSA) (EFSA). EFSA has also published a scientific opinion on the tolerable upper intake level for vitamin D (EFSA). EFSA’s vitamin K dietary reference value opinion notes uncertainty in available data related to vitamin K biomarkers, intake, and absorption of phylloquinone and menaquinones (EFSA).

Evidence Overview

The overall human evidence for Vitamin D3 + Vitamin K2 is most developed for Bone Health, mixed for Cardiovascular Health, and early-stage for Diabetes and Glycemic Control (Review) (Research) (Research). Bone research includes randomized trials and meta-analyses measuring BMD, osteocalcin carboxylation, and bone-turnover markers, especially in postmenopausal or older adult populations (Research) (Review). Confidence is not higher because studies differ by vitamin K form, vitamin D form, calcium or mineral co-use, trial duration, and clinical endpoint (Review) (Review).

For Bone Health, the strongest pattern is improvement in vitamin K–related biomarkers such as undercarboxylated osteocalcin, while BMD findings are more variable by site and trial design (Research) (Research). A meta-analysis of vitamin D + vitamin K trials reported increased total BMD and decreased undercarboxylated osteocalcin, but individual trials show that effects are not uniform across all skeletal sites and interventions (Review) (Research).

For Cardiovascular Health, the evidence has become more clinically specific because D3+K2 trials have measured coronary artery calcification progression in defined populations (Research) (Research). The AVADEC coronary analysis did not show a significant overall reduction in mean CAC progression, while the DANCODE trial reported reduced CAC progression in adults with CAC ≥400 AU (Research) (Research). This pattern suggests that baseline calcification severity and endpoint selection are important for interpreting the cardiovascular literature, but it does not establish broad cardiovascular prevention claims (Review).

For Diabetes and Glycemic Control, one small randomized trial reported glycemic and osteocalcin-related biomarker changes after 3 months of D3+K2 in adults with type 2 diabetes (Research). This is a relevant human signal, but it is not yet supported by the same breadth of replicated trials seen in bone-related research (Research) (Review).

Future confidence would be strengthened by larger trials that separately compare D3+K2 with D3 alone, K2 alone, calcium-containing combinations, and placebo across clearly defined populations (Review). More consistent reporting of vitamin D status, vitamin K biomarkers, MK-4 versus MK-7 form, calcium intake, anticoagulant exclusion criteria, and hard clinical endpoints would also make the evidence easier to interpret (Review) (Review).

Evidence Confidence Classification

Limited / Mixed is the overall human evidence classification for Vitamin D3 + Vitamin K2, because randomized human studies exist across bone, vascular, and metabolic contexts, but findings vary by formulation, dose, population, co-intervention, and endpoint (Review) (Review).

The evidence is stronger for bone-related biomarkers and selected BMD outcomes than for broad clinical claims, because multiple trials and reviews examine osteocalcin and BMD but individual findings remain inconsistent across skeletal sites and study designs (Review) (Research). Cardiovascular evidence is mixed because some trials report no overall effect while newer severe-CAC research reports reduced CAC progression in a selected population (Research) (Research). Glycemic evidence is emerging because it currently rests on smaller human trial evidence rather than broad replication (Research).

Similar Ingredients & Comparators

Similar supplement-style ingredients:

• Vitamin D3
• Vitamin D2
• 25-hydroxyvitamin D
• Vitamin K1
• Vitamin K2 MK-4
• Vitamin K2 MK-7
• Calcium
• Magnesium
• Boron
• Collagen peptides
• Hydroxyapatite

Medical / pharma comparator categories:

• Osteoporosis medications
• Calcium-regulating medications
• Anticoagulants
• Lipid-lowering therapies
• Diabetes medications
• Chronic kidney disease mineral-bone disorder therapies

Combination Context

Vitamin D3 + Vitamin K2:
This is the direct combination most relevant to the article, and it has been studied in type 2 diabetes and cardiovascular calcification research (Research) (Research). The main limitation is that outcomes differ by population, dose, and endpoint (Review).

Vitamin D3 + Vitamin K2 + Calcium:
Several bone studies use vitamin K2 as an add-on to calcium and vitamin D backgrounds, especially in postmenopausal women or osteopenia contexts (Research) (Research). This design makes it difficult to isolate the independent contribution of K2 because calcium and vitamin D are also active study components (Research).

Vitamin D + Vitamin K1 + Calcium:
Vitamin K1 has been studied with vitamin D and calcium in older adult bone research, including trials that measured BMD and vitamin K biomarkers (Research) (Research). These studies provide adjacent vitamin D + K context but should not be treated as direct vitamin K2 evidence.

Vitamin D + Vitamin K + Minerals:
A carotid elasticity study used minerals plus vitamin D and vitamin K1 in postmenopausal women and reported maintained carotid elastic properties in the combined intervention group (Research). This combination is informative for vascular marker research but includes multiple active components beyond D and K.

Active vitamin D analog + Vitamin K2:
Alfacalcidol plus menatetrenone has been studied in postmenopausal bone research, where investigators measured BMD and bone-turnover markers (Research) (Research). This evidence is adjacent to D3+K2 but should be distinguished from ordinary cholecalciferol-based combinations.

FAQ

What is Vitamin D3 + Vitamin K2?

Vitamin D3 + Vitamin K2 is a combination of cholecalciferol and menaquinone vitamin K forms (NIH ODS) (NIH ODS). Vitamin D3 is involved in calcium and bone-related physiology, while vitamin K participates in activation of vitamin K–dependent proteins (NIH ODS) (NIH ODS). Human research on the combination mainly examines bone, vascular calcification, and selected metabolic biomarkers (Review).

What does human research study it for?

Human research studies Vitamin D3 + Vitamin K2 mainly for Bone Health, Cardiovascular Health, Nutrition and Deficiencies, and Diabetes and Glycemic Control (Review) (Research). Bone studies often measure BMD and osteocalcin carboxylation, while cardiovascular studies measure calcification or vessel-function outcomes (Research) (Research). The metabolic evidence includes a small randomized trial in adults with type 2 diabetes (Research).

What are the best-supported uses?

The best-supported research area is Bone Health, especially biomarker outcomes such as undercarboxylated osteocalcin and some BMD endpoints in postmenopausal or older adult populations (Review) (Review). This does not mean every bone trial is positive, because longer MK-7 add-on research did not show significant BMD differences versus calcium and vitamin D background supplementation (Research). Cardiovascular evidence is clinically relevant but mixed across trials and populations (Research) (Research).

Where is evidence mixed or limited?

Evidence is mixed in Cardiovascular Health because some D3+K2 calcification research reports no significant overall effect while another trial in severe CAC reports reduced progression (Research) (Research). Evidence is limited in Diabetes and Glycemic Control because the direct D3+K2 human evidence includes a small 3-month randomized trial rather than large replicated studies (Research). Evidence is also complicated by differences between K1, MK-4, and MK-7 studies (NIH ODS) (Research).

How quickly does it act?

Human D3+K2 studies usually measure effects over months or years, not minutes or hours (Research) (Research). A type 2 diabetes trial measured outcomes after 3 months, while cardiovascular calcification trials used 2-year timeframes (Research) (Research). Bone studies commonly use 6-month to 3-year designs depending on the outcome measured (Research) (Research).

What affects absorption and variability?

Absorption and variability depend on component form, because vitamin D forms and vitamin K forms differ in handling and blood-level response (Review) (Research). MK-4 and MK-7 should not be treated as identical because comparative human studies show different serum response patterns (Research). Study interpretation also varies with baseline nutrient status, calcium co-use, population, and endpoint measured (Review).

Is tolerance reported?

A clear tolerance pattern for D3+K2 as a combined ingredient is not established in the cited human outcome trials (Research) (Research). Safety interpretation instead focuses on adverse-event monitoring in trials and known component-level issues such as vitamin K interaction with warfarin and vitamin D excess-intake concerns (NIH ODS) (NIH ODS). A vitamin K2 meta-analysis in postmenopausal osteoporosis found no significant pooled adverse-reaction difference versus controls in included trials (Review).

Why do studies disagree?

Studies disagree because they do not all use the same ingredients, doses, populations, or endpoints (Review). Some studies use K1, some use MK-4, some use MK-7, and some include calcium, minerals, or active vitamin D analogs (Research) (Research) (Research). Cardiovascular findings may also depend on baseline calcification severity and whether the endpoint is CAC progression, aortic valve calcification, carotid elasticity, or arterial microcalcification (Research) (Research).

What ingredients is it commonly combined with and why?

Vitamin D3 + Vitamin K2 is commonly studied with calcium in bone research because calcium, vitamin D, and vitamin K biology intersect in skeletal mineralization and osteocalcin activation (Research) (Review). Some trials use minerals with vitamin D and vitamin K to study vascular or bone-related outcomes (Research). These multi-ingredient designs can make it harder to isolate the effect of D3+K2 alone (Research).

What foods naturally contain this ingredient?

Vitamin D3 occurs in certain animal-derived foods and is also produced in skin after ultraviolet exposure (NIH ODS). Vitamin K2 menaquinones occur in certain animal-derived and fermented foods, while vitamin K1 is concentrated in green leafy vegetables (NIH ODS). A combined D3+K2 supplement is therefore a formulated pairing of two vitamin categories rather than a single naturally occurring molecule (NIH ODS) (NIH ODS).

How is it regulated?

In the United States, FDA states that dietary supplements are regulated as foods, not as drugs (FDA). FDA also states that firms are responsible for evaluating the safety and labeling of dietary supplements before marketing (FDA). In the European context, EFSA has published dietary reference values for vitamin D and vitamin K, as well as a tolerable upper intake level opinion for vitamin D (EFSA) (EFSA) (EFSA).

Resources

Vitamin D Fact Sheet for Health Professionals — NIH ODS — https://ods.od.nih.gov/factsheets/VITAMIND/HealthProfessional/

Vitamin K Fact Sheet for Health Professionals — NIH ODS — https://ods.od.nih.gov/factsheets/vitaminK-HealthProfessional/

Dietary Supplements — FDA — https://www.fda.gov/consumers/consumer-updates/dietary-supplements

Dietary Supplements Program — FDA — https://www.fda.gov/food/dietary-supplements

Dietary Reference Values for Vitamin D — EFSA — https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2016.4547

Dietary Reference Values for Vitamin K — EFSA — https://doi.org/10.2903/j.efsa.2017.4780

Tolerable Upper Intake Level for Vitamin D — EFSA — https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2012.2813

Vitamin K Combined with Vitamin D and Human Bone Quality Meta-Analysis — PubMed — https://pubmed.ncbi.nlm.nih.gov/32219282/

Vitamin D and K in Bone and Cardiovascular Health — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC5613455/

Vitamin K2 in Postmenopausal Osteoporosis Meta-Analysis — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC9403798/

DANCODE Trial — PubMed — https://pubmed.ncbi.nlm.nih.gov/42661461/

D3+K2 in Type 2 Diabetes Trial — PubMed — https://pubmed.ncbi.nlm.nih.gov/32831908/